New research has found that CBD can be used to relieve the postop pain patients experience after undergoing rotator cuff surgeries. CBD works like any other anti-inflammatory drug, without inducing any of those side effects that other medications cause such as stomach irritation. The substance t has multiple mechanisms of action, including reducing inflammation contributing to the pain.
The research findings were recently presented at the annual meeting of the American Orthopedic Society of Sports Medicine, which was held in Colorado Springs, Colorado.
The study was led by sports orthopedic specialist, Dr. Michael J. Alaia, of NYU Langone Health. It should be noted that the findings have not yet been published in a medical journal.
The researchers established a multi-center trial that involved 80 subjects aged between 18 and 75. The subjects were divided into two groups, with one group receiving a placebo while the other received CBD; both groups received the treatment for a two-week period. The CBD dosage administered depended on the weight of the subject, with trained facilitators administering either 25 mg or 50 mg.
The researchers recorded the pain levels of every participant on the first, second, seventh and fourteenth day. They used a visual analog scale (VAS) for opioid consumption, pain and satisfaction with pain control. They also measured liver function for every participant on the seventh and fourteenth days to evaluate safety while also monitoring for nausea.
In their report, the researchers note that they observed that on the first day, the pain score was considerably lower for participants who received CBD. They also found that there were statistically significant differences in the consumption of opioids between the two groups, noting that patient satisfaction with pain control also favored the CBD group.
The researchers also observed that subjects who received 50 mg of CBD recorded lower pain scores on the first say and high satisfaction with pain control on the first and second days, in comparison to subjects who received 25 mg of the same as well as those who received the placebo.
However, the researchers note that by the seventh day of the trial, no significant differences in opioid consumption, VAS score or satisfaction with pain control were recorded. Additionally, no substantial differences in liver function or nausea were observed.
In a statement, Alaia explained that the group’s findings showed that CBD was effective and safe in reducing pain in the immediate postop period after a rotator cuff surgery. He noted that the use of CBD should be considered in post-op multimodal pain control.
These promising results about the efficacy of cannabidiol in managing pain after one undergoes some surgical procedures suggest that there is plenty more to be discovered about the medicinal effects of different marijuana products, such as those manufactured by state-legal companies such as Prime Harvest Inc.
NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
